TargetBeta
GPRC5D
G protein-coupled receptor class C group 5 member D · G protein-coupled receptors, Class C orphans
11 programs in company-led studies act on GPRC5D, from 9 companies: 5 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 77 running | CD3E, TNFRSF17 | a judged reading |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 44 running | CD3E, TNFRSF17 | NCIt |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 33 running | CD3E | the studies' text |
| arlocabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 32 running | – | a judged reading |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 22 running | CD3E | the studies' text |
| MBS314 for Injectionrule | Beijing Mabworks Biotech | phase 2 | 11 running | CD3E | the studies' text |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 11 running | CD28, CD3E | the studies' text |
| vemzatatug vedotin | AstraZeneca | phase 2 | 11 running | – | a judged reading |
| Anti-GPRC5D Monoclonal Antibody SAR446523 | Sanofi | phase 1 | 11 running | – | the company's pipeline |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 11 running | CD3E | the company's pipeline |
| tunlucabtagene autoleucel | Bristol-Myers Squibb | phase 1 | 11 running | TNFRSF17 | a judged reading |
Also acted on by the same programs
Conditions their studies are in
- Multiple Myeloma, 11 programs
- Lupus Erythematosus, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026QLS4131 · Qilu Pharmaceutical · phase 3 · NCT07001839
- Dec 31, 2026GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003 · Innovent Biologics · phase 3 · NCT07764861
- Apr 19, 2027ramantamig · Johnson & Johnson · phase 3 · NCT05652335
- Dec 2027QLS32015 · Qilu Pharmaceutical · phase 3 · NCT07138209
- Dec 2027MBS314 for Injection · Beijing Mabworks Biotech · phase 2 · NCT07911748
- Dec 30, 2027arlocabtagene autoleucel · Bristol-Myers Squibb · phase 3 · NCT06615479
- Jan 24, 2028vemzatatug vedotin · AstraZeneca · phase 2 · NCT06106945
- May 2, 2030tunlucabtagene autoleucel · Bristol-Myers Squibb · phase 1 · NCT06153251
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.